UnknownPhase 3NCT06089122

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Azidus Brasil
Principal Investigator
Luciana Ferrara, RNP
Azidus Brasil
Intervention
IVIG(biological)
Enrollment
50 enrolled
Eligibility
6-60 years · All sexes
Timeline
20242025

Collaborators

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06089122 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency

← Back to all trials